ラリマー・セラピューティクス
Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.30 | $0 | -$44M |
| 2026 Q1 | -0.35 | $0 | -$45M |
| 2025 Q4 | -0.73 | $0 | -$39M |
| 2025 Q3 | -0.61 | $0 | -$29M |
| 2025 Q2 | -0.41 | $0 | -$19M |
| 2025 Q1 | -0.46 | $0 | -$27M |
| 2024 Q4 |
| -0.45 |
| $0 |
| -$22M |
| 2024 Q3 | -0.24 | $0 | -$25M |